Gyros Platform Ramps Up Immunoassay Capacity at ICON Development Solutions
News Mar 12, 2010
Gyros AB has confirmed that ICON Development Solutions, a division of ICON plc, has ramped up its capacity to develop and run immunoassays through the purchase of a third Gyrolab™ workstation.
John Allinson, Vice President Biomarker Lab Services at ICON Development Solutions, explained the reasoning behind the decision: “We are constantly looking for innovative systems that will deliver efficient, high quality and cost-effective bioanalytical services to our clients. Investing in the Gyros™ platform enables us to make significant gains in assay quality, performance and productivity. We can improve the workflows of multiple projects through leveraging a unique, automated, yet open, platform on which we can develop and run many different immunoassays whilst also overcoming many of the challenges associated with conventional immunoassays.”
Mr. Allinson continued, “The systems have become almost a ‘one-stop shop’ to meet our immunoassay requirements for some projects whilst complementing other platforms for others. We are also planning to introduce Gyrolab workstations into our US facilities in the near future to enable them to benefit in a similar way”.
Erik Wallden, CEO at Gyros, added: “We are extremely gratified to see that our systems contribute so significantly to the success of CRO’s. ICON is an excellent example of a clearly emerging trend in which forward-thinking contract service organizations strengthen their competitive edge by investing in innovative solutions that better meet their clients’ needs. This trend is particularly strong in the European region where CRO’s are winning contracts from around the world.”
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018